You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博暉創新(300318.SZ):雲南博暉擬投資13.8億元建設曲靖血液製品生產基地
格隆匯 02-08 20:10

格隆匯 2 月 8日丨博暉創新(300318.SZ)公佈,為做大做強公司血液製品業務,2019年4月29日,公司與曲靖市人民政府在雲南曲靖簽署了《關於血液製品生產基地項目投資合作戰略框架協議》,根據該戰略框架協議的約定,公司控股子公司河北大安製藥有限公司(“河北大安”)設立了雲南博暉創新生物有限公司(“雲南博暉”)並將該公司作為項目公司承擔曲靖血液製品生產基地建設等工作。

現雲南博暉擬投資13.8億元建設上述血液製品生產基地,生產人血白蛋白、人免疫球蛋白以及人凝血因子等血液製品。

雲南博暉在雲南省曲靖市建設血液製品生產基地,生產人血白蛋白、人免疫球蛋白以及人凝血因子等血液製品。另配套建設一批採漿站,為生產基地提供血漿。該項目屬於生物醫藥類項目,全部建成後,可達到年加工血漿量1500噸的規模,生產的各類血液製品將有利於緩解市場上血液製品的緊缺狀況。

上述投資項目將為公司血液製品業務規模擴張奠定有力基礎,有利於提升公司血液製品業務生產運營水平,進一步做大做強血液製品業務。對公司業績的影響視後續項目的具體實施情況而定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account